Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Current Assets (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Current Assets for 7 consecutive years, with $80.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets fell 2.1% year-over-year to $80.2 million, compared with a TTM value of $80.2 million through Dec 2025, down 2.1%, and an annual FY2025 reading of $80.2 million, down 2.1% over the prior year.
  • Current Assets was $80.2 million for Q4 2025 at aTYR PHARMA, down from $93.0 million in the prior quarter.
  • Across five years, Current Assets topped out at $121.6 million in Q3 2021 and bottomed at $46.4 million in Q2 2021.
  • Average Current Assets over 5 years is $91.5 million, with a median of $91.7 million recorded in 2024.
  • The sharpest move saw Current Assets soared 219.63% in 2021, then plummeted 30.38% in 2022.
  • Year by year, Current Assets stood at $113.6 million in 2021, then dropped by 28.79% to $80.9 million in 2022, then grew by 27.35% to $103.0 million in 2023, then decreased by 20.43% to $82.0 million in 2024, then decreased by 2.1% to $80.2 million in 2025.
  • Business Quant data shows Current Assets for ATYR at $80.2 million in Q4 2025, $93.0 million in Q3 2025, and $87.5 million in Q2 2025.